The phase 3 OptiTROP-Lung05 trial (NCT06448312) evaluating the efficacy and safety profile of sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in combination with pembrolizumab (Keytruda) vs pembrolizumab monotherapy as first-line treatment of…
Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in NSCLC | Targeted Oncology
